Experienced in Pituitary Tumor

Dr. Ashley L. Sumrall

Hematology | Oncology
Atrium Health
Atrium Health Levine Cancer Institute (Medical Oncology & Immunotherapy)
1021 Morehead Medical Drive, Suite 6100, 
Charlotte, NC 
On Staff At
Accepting New Patients
Offers Telehealth
Experienced in Pituitary Tumor
Atrium Health
Atrium Health Levine Cancer Institute (Medical Oncology & Immunotherapy)
1021 Morehead Medical Drive, Suite 6100, 
Charlotte, NC 
OverviewInsuranceLocationsClinical Research

Overview

Ashley Sumrall is a Hematologist and an Oncologist in Charlotte, North Carolina. Dr. Sumrall is rated as an Experienced provider by MediFind in the treatment of Pituitary Tumor. Her top areas of expertise are Glioma, Gliosarcoma, Brain Tumor, and Astrocytoma. Dr. Sumrall is currently accepting new patients.

Her clinical research consists of co-authoring 35 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
The University Of Mississippi
Residency
The University of Mississippi
Specialties
Hematology
Oncology
Licenses
Internal Medicine in NC
Board Certifications
American Board Of Internal Medicine
American Board Of Internal Medicine, Medical Oncology
Fellowships
Duke University
Hospital Affiliations
Atrium Health Union
Atrium Health Cleveland
Carolinas Medical Center/behav Health
Atrium Health University City
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Atrium Health Levine Cancer Institute (Medical Oncology & Immunotherapy)
1021 Morehead Medical Drive, Suite 6100, Charlotte, NC 28204
Call: 980-442-5310

Additional Areas of Focus

Dr. Sumrall has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Pituitary Tumor
Thyroid Cancer
Neurofibromatosis Type 1 (NF1)
Ovarian Cancer
Breast Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Genomically-Guided Treatment Trial in Brain Metastases
Genomically-Guided Treatment Trial in Brain Metastases
Enrollment Status: Suspended
Publish Date: February 04, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Paxalisib, Entrectinib
Study Phase: Phase 2
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: January 26, 2026
Intervention Type: Diagnostic test
Study Phase: Not Applicable
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: December 18, 2025
Intervention Type: Other, Biological, Procedure, Drug, Radiation, Device
Study Drugs: Ipilimumab, Nivolumab, Temozolomide
Study Phase: Phase 2/Phase 3
A Phase II, Open-label Study of ONC201 in Adults With Recurrent High-grade Glioma
A Phase II, Open-label Study of ONC201 in Adults With Recurrent High-grade Glioma
Enrollment Status: Terminated
Publish Date: July 28, 2025
Intervention Type: Drug
Study Drug: ONC201
Study Phase: Phase 2
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
Enrollment Status: Completed
Publish Date: May 11, 2023
Intervention Type: Drug, Radiation
Study Drugs: Temozolomide, Depatuxizumab
Study Phase: Phase 3
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Enrollment Status: Terminated
Publish Date: March 23, 2023
Intervention Type: Drug, Other
Study Phase: Phase 2
View 6 Less Clinical Trials

35 Total Publications

Correction: Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.
Correction: Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.
Journal: Cancer discovery
Published: January 30, 2025
View All 35 Publications

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sumrall's expertise for a condition
ConditionClose
  • Elite
  • Brain Tumor
    Dr. Sumrall is
    Elite
    . Learn about Brain Tumor.
    See more Brain Tumor experts
  • Glioma
    Dr. Sumrall is
    Elite
    . Learn about Glioma.
    See more Glioma experts
  • Gliosarcoma
    Dr. Sumrall is
    Elite
    . Learn about Gliosarcoma.
    See more Gliosarcoma experts
  • Distinguished
  • Astrocytoma
    Dr. Sumrall is
    Distinguished
    . Learn about Astrocytoma.
    See more Astrocytoma experts
  • Atypical Teratoid Rhabdoid Tumor (ATRT)
    Dr. Sumrall is
    Distinguished
    . Learn about Atypical Teratoid Rhabdoid Tumor (ATRT).
    See more Atypical Teratoid Rhabdoid Tumor (ATRT) experts
  • Cowden Syndrome
    Dr. Sumrall is
    Distinguished
    . Learn about Cowden Syndrome.
    See more Cowden Syndrome experts
  • Embryonal Tumor with Multilayered Rosettes
    Dr. Sumrall is
    Distinguished
    . Learn about Embryonal Tumor with Multilayered Rosettes.
    See more Embryonal Tumor with Multilayered Rosettes experts
  • Ependymoma
    Dr. Sumrall is
    Distinguished
    . Learn about Ependymoma.
    See more Ependymoma experts
  • Glioblastoma
    Dr. Sumrall is
    Distinguished
    . Learn about Glioblastoma.
    See more Glioblastoma experts
View All 21 Distinguished Conditions
  • Advanced
  • Brain Stem Cancer
    Dr. Sumrall is
    Advanced
    . Learn about Brain Stem Cancer.
    See more Brain Stem Cancer experts
  • Breast Cancer
    Dr. Sumrall is
    Advanced
    . Learn about Breast Cancer.
    See more Breast Cancer experts
  • Choroid Plexus Papilloma
    Dr. Sumrall is
    Advanced
    . Learn about Choroid Plexus Papilloma.
    See more Choroid Plexus Papilloma experts
  • Diffuse Midline Glioma H3 K27M-Mutant
    Dr. Sumrall is
    Advanced
    . Learn about Diffuse Midline Glioma H3 K27M-Mutant.
    See more Diffuse Midline Glioma H3 K27M-Mutant experts
  • Dysembryoplastic Neuroepithelial Tumors (DNET)
    Dr. Sumrall is
    Advanced
    . Learn about Dysembryoplastic Neuroepithelial Tumors (DNET).
    See more Dysembryoplastic Neuroepithelial Tumors (DNET) experts
  • Inflammatory Breast Cancer
    Dr. Sumrall is
    Advanced
    . Learn about Inflammatory Breast Cancer.
    See more Inflammatory Breast Cancer experts
View All 10 Advanced Conditions
  • Experienced
  • ALK-Positive Non-Small Cell Lung Cancer
    Dr. Sumrall is
    Experienced
    . Learn about ALK-Positive Non-Small Cell Lung Cancer.
    See more ALK-Positive Non-Small Cell Lung Cancer experts
  • Anaplastic Thyroid Cancer
    Dr. Sumrall is
    Experienced
    . Learn about Anaplastic Thyroid Cancer.
    See more Anaplastic Thyroid Cancer experts
  • Angiosarcoma
    Dr. Sumrall is
    Experienced
    . Learn about Angiosarcoma.
    See more Angiosarcoma experts
  • Cerebral Ventricle Cancer
    Dr. Sumrall is
    Experienced
    . Learn about Cerebral Ventricle Cancer.
    See more Cerebral Ventricle Cancer experts
  • Colorectal Cancer
    Dr. Sumrall is
    Experienced
    . Learn about Colorectal Cancer.
    See more Colorectal Cancer experts
  • Congenital Generalized Fibromatosis
    Dr. Sumrall is
    Experienced
    . Learn about Congenital Generalized Fibromatosis.
    See more Congenital Generalized Fibromatosis experts
View All 38 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.